Disease family/type
| Condition | Treatment name, Manufacturer | Therapy type | Population |
Cancers |
Blood cancer (Leukaemia; lymphoma; myeloma; myelodysplastic syndrome; myeloproliferative disorders)
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells) |
All ages |
Cancers |
Diffuse large B-cell lymphoma
|
Kymriah, Novartis
Yescarta, Kite Pharma
|
Hybrid gene-cell therapy (CAR-T Therapy)
|
Adults |
Cancers |
Mantle cell lymphoma |
Tecartus, Kite Pharma / Gilead |
Hybrid gene-cell therapy (CAR-T therapy) |
Adults |
Cancers |
Primary mediastinal B-cell lymphoma
|
Yescarta, Kite Pharma |
Hybrid gene-cell therapy (CAR-T Therapy)
|
Adults |
Cancers |
B-Cell Acute Lymphoblastic Leukaemia
|
Kymriah, Novartis
|
Hybrid gene-cell therapy (CAR-T Therapy)
|
< 25 years |
Cancers |
Adult B-Cell Acute Lymphoblastic Leukaemia
|
Yescarta, Kite Pharma |
Hybrid gene-cell therapy (CAR-T Therapy)
|
Adults |
Cancers |
Melanoma |
Imlygic, Amgen |
Gene therapy
|
Adults |
Cancers |
Multiple myeloma (adult) |
Abecma, Bristol-Myers-Squib |
Hybrid gene-cell therapy (CAR-T Therapy) |
Adults |
Immune-mediated blood disorders
|
Severe Combined Immunodeficiency (SCID) syndrome
|
Strimvelis, Orchard Therapeutics/ GlaxoSmithKline |
Hybrid gene-cell therapy (Haematopoietic stem cells containing altered genetic material)
|
Children |
Immune-mediated blood disorders |
T-Cell deficiency (DiGeorge Syndrome, ataxia-telangiectasia)
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells) |
All ages |
Immune-mediated blood disorders
|
Acquired loss of immune function |
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Blood disorders (other)
|
Anaemias (aplastic anaemia; pure red cell anaemia; paroxysmal nocturnal haemoglobinuria)
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells) |
All ages |
Blood disorders (other)
|
Beta-Thalassemia |
Zynteglo, Bluebird Bio |
Hybrid gene-cell therapy (Haematopoietic stem cells)
|
< 12 years |
Blood disorders (other)
|
Sickle cell disease |
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Blood disorders (other)
|
Haemoglopinopathies
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Blood disorders (other)
|
Immune-mediated cytopenia
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Blood disorders (other)
|
Haemophagocytic lymphohistiocytosis (HLH syndrome)
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Immune-related disorders
|
Crohn’s Disease (anal fistula) |
Alofisel, Takeda |
Hybrid gene-cell therapy (Haematopoietic stem cells)
|
All ages |
Infectious diseases
|
HIV/AIDS |
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Neurological disorders |
Cerebral adrenoleukodystophy |
Skysona, Bluebird Bio |
Gene therapy |
Children |
Neurological disorders
|
Metachromatic leukodystrophy |
Libmeldy, Orchard Therapeutics |
Hybrid gene-cell therapy (Haematopoietic stem cells)
|
Children |
Neurological disorders |
Multiple sclerosis
|
Provided in hospitals
|
Stem cell therapy (Haematopoietic stem cells)
|
All ages |
Neurological disorders |
Spinal muscular atrophy |
Zolgensma, Novartis |
Gene therapy |
Children |
Vision loss |
Retinal dystrophy |
Luxturna, Novartis |
Gene therapy |
All ages |
Acquired injury, eye
|
Corneal damage (e.g. chemical burn) |
Holoclar, Chiesi |
Tissue Therapy (Limbal stem cells)
|
All ages |
Acquired injury, orthopaedic
|
Cartilage damage (knee joint) |
Spherox, CO.DON AG |
Cell therapy |
Adults |